Blockade of PD-1/PD-L1 and CTLA-4 is effective up to 50% of the patients with immune sensitive cancers such as melanoma, non-small cell lung cancer, squamous cell carcinoma of head and neck cancers, renal cell carcinoma, bladder cancer, and Hodgkin’s lymphoma according to the FDA’s objective response criteria [189]. This evidence concerns the gene CD274 and melanoma.